Taken together, the study suggests that targeting the microglial APOE4-ITGB8-TGFβ pathway could potentially restore the MGnD microglial phenotype, which provides a promising therapeutic target in AD [65]. This evidence concerns the gene TGFB1 and Alzheimer disease.